AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.

Wednesday, the FDA approved a combination of the drug and Roche’s Gazyva for previously untreated patients with CLL or small lymphocytic leukemia (SLL). The regimen, approved speedily under the agency’s Real-Time Oncology Review, represents a chemo-free option for patients.